Clinical Trial Update: Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating stopping dasatinib in patients with chronic phase chronic myeloid leukemia who have stable complete molecular response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Phase Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-11-02